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SUPERIOR COURT
CIVIL ACTION
DOCKET NO. CV-12-

STATE OF MAINE
KENNEBEC, ss.

STATE of MAINE,
Plaintiff,
V.

)

)
)
)
)

ABBOTT LABORATORIES,
Defendant

)

COMPLAINT
(Injunctive Relief Requested)

)
)
)
INTRODUCTION

Plaintiff State of Maine, by and through its Attorney General, alleges claims for relief
based on violations of Maine’s Unfair Trade Practices Act (“UTPA”), 5 M.R.S. §§ 205-A
through 214,
PARTIES
1.

Plaintiff State of Maine (the “State”) is a sovereign state, having its capital at

Augusta, Maine, that brings this action by and through its Attorney General pursuant to 5 M.R.S.
§§ 191 and 209 and the powers vested in him by common law.
2.

Defendant Abbott Laboratories (“Abbott” or “Defendant”) is an Illinois

corporation with its principal place of business atl 00 Abbott Park Road, D-322 AP6D, Illinois,
60064.
3.

Abbott transacts business in the State of Maine by advertising, soliciting, selling,

promoting and distributing prescription drugs, including Depakote® (“Depakote”), to consumers
in the State of Maine and nationwide.
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JURISDICTION AND VENUE
4.

This Court has jurisdiction over this action, pursuant to 4 M.R.S. § 105 and

5 M.R.S, § 209. This Court has jurisdiction over Defendant, pursuant to 5 M.R.S. § 209 and 14
M.R.S. § 704-A,
5.

Venue is properly laid in Kennebec County, pursuant to 5 M.R.S. § 209.
STATUTORY BACKGROUND

6.

Pursuant to 5 M.R.S. § 207, “unfair or deceptive acts or practices in the conduct

of any trade or commerce are. . . unlawful.”
7.

Pursuant to 5 M.R.S. § 209:
Whenever the Attorney General has reason to believe
that any person is using or is about to use any method, act
or practice declared by section 207 to be unlawful, and that
proceedings would be in the public interest, he may bring
an action in the name of the State against such person to
restrain by temporary or permanent injunction the use of
such method, act or practice and the court may make such
other orders or judgments as may be necessary to restore to
any person who has suffered any ascertainable loss by
reason of the use or employment of such unlawful method,
act or practice, any moneys or property, real or personal,
which may have been acquired by means of such method,
act or practice.. . .

8.

Pursuant to 5 M.R.S. § 209, each intentional violation of 5 M.R.S. § 207 that

results from unfair or deceptive conduct is a civil violation for which a penalty of up to $10,000
may be imposed.
9.

Pursuant to 14 M.R.S. § 1522(1)(A), should the State prevail in an action brought

by the Attorney General to enforce 5 M.R.S.A. § 207, the Court shall allow litigation costs,
including court costs, reasonable attorney’s fees, and reasonable expert witness fees.

FACTS
10.

Drug companies are prohibited by the Food Drug and Cosmetic Act of 1938, 21

USCA § 321 etseq (“FDCA”) from promoting drugs for indications (uses) that are not approved
by the U.S. Food and Drug Administration (“FDA”).
11.

In order to obtain FDA approval to lawfully market a drug in the United States, a

drug company must submit clinical trials that prove by substantial evidence that the drug is safe
and effective for its intended use.
12.

Abbott obtained FDA approval to market the prescription drug Depakote only for

treatment of seizure disorders, mania associated with bipolar disorder, and prophylaxis of
migraines.
13.

In addition to the indications approved by the FDA, Abbott knew that doctors

prescribed Depakote “off-label” to treat a number of other indications, including agitation
associated with dementia, and as combination therapy with antipsychotic medications to treat
schizophrenia.
14.

Although Abbott did not possess substantial evidence to substantiate a claim that

Depakote is effective for the treatment of agitation associated with dementia, or as adjunct
therapy with antipsychotics to treat schizophrenia, Abbott chose to bypass the regulatory process
and to engage in off-label promotion for these indications.
15.

The decision to promote Depakote off-label was driven by Abbott's

understanding that the studies required by the FDA to demonstrate safety and efficacy for these
indications would be expensive and the results of the required studies might not be sufficient to
support Abbott's application.

16.

Abbott was also concerned that even if the FDA approved the new indications, the

patent on Depakote would expire at about the same time as FDA’s approval, and Abbott would
not be able to take advantage of the approval before cheaper generics captured the market.
17.

Abbott instructed its sales representatives to distribute and detail studies that

found Depakote to be effective for the off-label uses.

However, these studies were not

competent and reliable scientific evidence and did not substantiate efficacy.
18.

Abbott also promoted Depakote at supposedly independent Continuing Medical

Education events. In fact, these events were promotional in nature and an integral part o f the
Abbott’s scheme to promote for the off-label uses.
19.

To support its efforts to promote Depakote for schizophrenia in combination with

antipsychotic drugs to treat schizophrenia, Abbott conducted a clinical trial relating to this use.
However, the result of this study was negative and showed the addition of Depakote to be
ineffective.

Nonetheless, Abbott continued to promote Depakote as an adjunct with

antipsychotic medications ,to treat schizophrenia and failed to timely publish or publicize the
negative study results.
20.

Similarly, even after Abbott learned about a well conducted, well designed

clinical trial that found Depakote to be ineffective for treatment of agitation associated with
dementia, Abbott continued to promote Depakote off-label for this indication.
i

COUNT 1
M aine Unfair Trade Practices Act
5 M.R.S, § 207

21.

The State realleges and incorporates each and every allegation contained in the

preceding paragraphs 1 through 20.

22.

In the course of advertising, soliciting, selling, promoting and distributing the

prescription drug Depakote, Abbott has engaged in a course of trade or commerce that violates 5
M.R.S. § 207 by representing that Depakote has sponsorship, approval, characteristics,
ingredients, uses, benefits, quantities or qualities that it does not have.
23.

Abbott's conduct, as described in Count 1, was intentional.
PRAYER FOR RELIEF

WHEREFORE, the State prays that this honorable Court enter an Order:
(a)

Issuing a permanent injunction prohibiting Defendant, its agents, employees,

and all other persons and entities, corporate or otherwise, in active concert or participation
with any of them, from engaging in unfair or deceptive conduct, as provided by 5 M.R.S.
§209;
(b)

Ordering Defendant to pay reasonable attorney fees and costs for the

prosecution and investigation of this action, as provided by 14 M.R.S. 1522(1)(A);
(c)

Ordering Defendant to pay civil penalties of up to $10,000 for each intentional

violation of 5 M.R.S. § 207, as provided by 5 M.R.S. § 209; and
(d)

Granting such other and further relief as the Court deems equitable and proper.

Dated: May H

, 2012

Respectfully submitted,
WILLIAM J. SCHNEIDER
Attorney General

Assistant Attorney General
Office of the Attorney General
6 State House Station
Augusta, ME 04333-0006
Telephone: 207-626-8800
Email: Carolvn.silsbv@maine.gov

